Therefore, studying the effect of the therapeutic CXL strategy on the various inhibitory, as well as regulatory SMADs, exposes the possibility of targeting TGF-β signaling pathway to improve wound healing and/or reduce scarring in KC patients37. This evidence concerns the gene TGFB1 and keratoconus.